MNTA—Judging by the stock price movement and volume over the last few minutes, someone must have liked what they heard.
The webcast was very good, but only a MNTA neophyte could have been surprised by anything that was said. Today’s peculiar price action might be related to the FDA response to Teva’s latest Copaxone CP.